MAPT and Alzheimer disease: Recent findings indicate that both Aβ and tau biomarkers in CSF reach plateau levels at different stages of the disease, reducing their utility in monitoring AD pathology as the disease progresses.35 In our sample, however, we observed significant differences in the levels of all CSF AD biomarkers between AD dementia and aMCI-AD.